Medytox: Positive on Share Buyback and RCPS Redemption, Q1 Operating Profit of 73 Billion Won

Completed full redemption and cancellation of all RCPS (440,635 shares, KRW 76.7 billion) on Feb 23, 2026
Direct acquisition of 37,644 common shares as treasury stock (Jan 29~Feb 12, 2026)
Consolidated Q1 sales KRW 60.7B (+22% YoY), operating profit KRW 7.3B (+34% YoY), net profit KRW 7.9B
Debt ratio increased to 48.7% (from 28.1% at year-end) due to higher borrowings
New product 'New Viju' (submental fat reduction, world's first cholic acid-based) launched domestically in March 2026
MT10109L (US FDA BLA) rejected; preparing resubmission
Trade secret lawsuit against Daewoong Pharmaceutical ongoing at appellate court (won at trial)
Two criminal cases for Pharmaceutical Affairs Act violations pending at appellate court